HBV-ISS (Dynavax).
Dynavax is developing HBV-ISS (Heplisav), a vaccine based on hepatitis B virus (HB V) antigens and Dynavax' s immunostimulatory DNA sequence (ISS) ISS-1018, an adjuvant that acts as a TLR-9 agonist, for the potential prevention and treatment of HBV infection.
Sung
Joseph Jao-Yiu
JJ
Department of Medicine and Therapeutics, 9/F Prince of Wales Hospital, 30-32 Ngan Shing Street, Shatin, Hong Kong, SAR, PR China. Josesung@cuhk.edu.hk
Lik-Yuen
Henry
H
D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000627:therapeutic use; D000328:Adult; D017326:Clinical Trials, Phase III as Topic; D004306:Dose-Response Relationship, Immunologic; D005500:Follow-Up Studies; D006509:Hepatitis B / Q000517:prevention & control*; D006514:Hepatitis B Surface Antigens / Q000008:administration & dosage* / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D007279:Injections, Subcutaneous; D013997:Time Factors; D051217:Toll-Like Receptor 9 / Q000819:agonists; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines; D051217:Toll-Like Receptor 9